
CLAIMS

1. A pharmaceutical combination comprising:

- a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,


and

- at least one MAPK pathway inhibitor, or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical combination of claim 1, wherein the MAPK pathway inhibitor is an inhibitor of one or both of a MEK kinase and a RAF kinase.

3. The pharmaceutical combination of claim 2 , wherein the MAPK pathway inhibitor is:

- the compound (2a):



(2a)

or a pharmaceutically acceptable salt thereof,

or

- the compound (2b):



(2b)

or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical combination of any one of claims 1 to 3, further comprising a pharmaceutically acceptable carrier.

5. The pharmaceutical combination of any one of claims 1 to 4, comprising at least one further compound chosen from anticancer compounds.

6. The pharmaceutical combination of any one of claims 1 to 5, for use as a medicament.

7. The use of pharmaceutical combination of any one of claims 1 to 6, in the manufacture of a medicament for treating cancer.

8. Use according to claim 7, wherein the cancer is chosen from the group consisting of: non-small cell lung cancer, breast cancer, pancreatic cancer, liver cancer, prostate cancer, bladder cancer, cervical cancer, thyroid cancer, colorectal cancer, liver cancer, muscle cancer, hematological malignancies, melanoma, endometrial cancer and pancreatic cancer.

9. Use according to claim 7, wherein the cancer is chosen from the group consisting of: colorectal cancer, endometrial cancer, hematological malignancies, thyroid cancer, breast cancer, melanoma, pancreatic cancer and prostate cancer.

10. The use according to claim 7, wherein administration of the compound of formula (I) is to be followed by the administration of the MAPK pathway inhibitor.

11. The use according to claim 7, wherein administration of the MAPK pathway inhibitor is to be followed by the administration of the compound of formula (I).

12. The use according to claim 7, wherein administration of the compound of formula (I) is to be followed by the administration of the compound (2a).

13. The use according to claim 7, wherein administration of the compound of formula (I) is to be followed by the administration of the compound (2b).

14. The use according to claim 7, wherein administration of the compound (2a) is to be followed by the administration of the compound of formula (I).


15. The use according to claim 7, wherein administration of the compound (2b) is to be followed by the administration of the compound of formula (I).

16. The use according to claim 7, wherein the compound of formula (I) and the MAPK pathway inhibitor are in amounts that produce a synergistic effect in reducing tumor volume.

17. The use according to claim 7, wherein the compound of formula (I) and the MAPK pathway inhibitor are in amounts that produce a combined effect of tumor stasis.

18. A product comprising:

- a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,


and

- at least one MAPK pathway inhibitor, or a pharmaceutically acceptable salt thereof,

as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.

19. A kit comprising:

- at least one compound of formula (I):




(I)

or a pharmaceutically acceptable salt thereof,

- at least one MAPK pathway inhibitor chosen from the group consisting of:

the compound (2a):



(2a)

or a pharmaceutically acceptable salt thereof,

and

- the compound (2b):



(2b)

or a pharmaceutically acceptable salt thereof,


as a combined preparation for simultaneous, separate or sequential use in anticancer therapy

- and optionally, instructions for use.

CLAIMS

1. A pharmaceutical combination comprising:

- a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,

and

- at least one MAPK pathway inhibitor, or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical combination of claim 1, wherein the MAPK pathway inhibitor is an inhibitor of one or both of a MEK kinase and a RAF kinase.

3. The pharmaceutical combination of claim 2, wherein the MAPK pathway inhibitor is a MEK inhibitor.

4. The pharmaceutical combination of claim 2, wherein the MAPK pathway inhibitor is a RAF inhibitor

5. The pharmaceutical combination of claim 2 , wherein the MAPK pathway inhibitor is:

- the compound (2a):



(2a)

or a pharmaceutically acceptable salt thereof,

or

- the compound (2b):



(2b)


or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical combination of claim 2, wherein the MAPK pathway inhibitor is the compound (2a) of formula:



or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical combination of claim 2, wherein the MAPK pathway inhibitor is the compound (2b) of formula:



or a pharmaceutically acceptable salt thereof.

8. The pharmaceutical combination of any one of claims 1 to 7, further comprising a pharmaceutically acceptable carrier.

9. The pharmaceutical combination of any one of claims 1 to 7, comprising at least one further compound chosen from anticancer compounds.

10. A medicament comprising the pharmaceutical combination of any one of claims 1 to 9.

11. A pharmaceutical composition comprising the pharmaceutical combination of any one of claims 1 to 9, and a pharmaceutically acceptable excipient.

12. The pharmaceutical combination of any one of claims 1 to 9, for use as a medicament.

13. The pharmaceutical combination of any one of claims 1 to 9, for use for the treatment of cancer.

14. The combination according to claim 13, wherein the cancer is chosen from the group consisting of: non-small cell lung cancer, breast cancer, pancreatic cancer, liver cancer, prostate cancer, bladder cancer, cervical cancer, thyroid cancer, colorectal cancer, liver cancer, muscle cancer, hematological malignancies, melanoma, endometrial cancer and pancreatic cancer.

15. The combination according to claim 13, wherein the cancer is chosen from the group consisting of: colorectal cancer, endometrial cancer, hematological malignancies, thyroid cancer, breast cancer, melanoma, pancreatic cancer and prostate cancer.

16. The combination according to claim 13, wherein administration of the compound of formula (I) is followed by the administration of the MAPK pathway inhibitor.

17. The combination according to claim 13, wherein administration of the MAPK pathway inhibitor is followed by the administration of the compound of formula (I).

18. The combination according to claim 13, wherein administration of the compound of formula (I) is followed by the administration of the compound (2a).

19. The combination according to claim 13, wherein administration of the compound of formula (I) is followed by the administration of the compound (2b).

20. The combination according to claim 13, wherein administration of the compound (2a) is followed by the administration of the compound of formula (I).

21. The combination according to claim 13, wherein administration of the compound (2b) is followed by the administration of the compound of formula (I).

22. The combination according to claim 13, wherein the compound of formula (I) and the MAPK pathway inhibitor are in amounts that produce a synergistic effect in reducing tumor volume.

23. The combination according to claim 13, wherein the compound of formula (I) and the MAPK pathway inhibitor are in amounts that produce a combined effect of tumor stasis.

24. The combination for its use according to claim 13, wherein the cancer is chosen from the group consisting of: non-small cell lung cancer, breast cancer, pancreatic cancer, liver cancer, prostate cancer, bladder cancer, cervical cancer, thyroid cancer, colorectal cancer, liver cancer, muscle cancer, hematological malignancies, melanoma, endometrial cancer and pancreatic cancer.

25. The combination for its use according to claim 13, wherein the cancer is chosen from the group consisting of: colorectal cancer, endometrial cancer, hematological malignancies, thyroid cancer, breast cancer, melanoma, pancreatic cancer and prostate cancer.

26. The combination for its use according to claim 13, by administration of the compound of formula (I) followed by the administration of the MAPK pathway inhibitor.

27. The combination for its use according to claim 13, by administration of the MAPK pathway inhibitor followed by the administration of the compound of formula (I).

28. The combination for its use according to claim 13, by administration of the compound of formula (I) followed by the administration of the compound (2a).

29. The combination for its use according to claim 13, by administration of the compound of formula (I) followed by the administration of the compound (2b).

30. The combination for its use according to claim 13, by administration of the compound (2a) followed by the administration of the compound of formula (I).


31. The combination for its use according to claim 13, by administration of the compound (2b) followed by the administration of the compound of formula (I).

32. The combination for its use according to claim 13, wherein the compound of formula (I) and the MAPK pathway inhibitor are in amounts that produce a synergistic effect in reducing tumor volume.

33. The combination for its use according to claim 13, wherein the compound of formula (I) and the MAPK pathway inhibitor are in amounts that produce a combined effect of tumor stasis.

34. A pharmaceutical combination comprising:

- a compound of formula (I):




(I)

or a pharmaceutically acceptable salt thereof,

and at least one MAPK pathway inhibitor chosen from the group consisting of:

- the compound (2a):



(2a)

or a pharmaceutically acceptable salt thereof,

and

60

- the compound (2b):




(2b)

or a pharmaceutically acceptable salt thereof,

for use for the treatment of cancer.

35. A product comprising:

- a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,


and

- at least one MAPK pathway inhibitor, or a pharmaceutically acceptable salt thereof,

as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.

36. A kit comprising:

- at least one compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,


- at least one MAPK pathway inhibitor, or a pharmaceutically acceptable salt thereof,

and

- optionally, instructions for use.

37. A kit comprising:

- at least one compound of formula (I):




(I)

or a pharmaceutically acceptable salt thereof,

- at least one MAPK pathway inhibitor chosen from the group consisting of:

the compound (2a):



(2a)

or a pharmaceutically acceptable salt thereof,

and

- the compound (2b):



(2b)

or a pharmaceutically acceptable salt thereof,

- and optionally, instructions for use.